Key result
High intra-tumoral periostin expression was an independent prognostic factor significantly associated with decreased cancer-specific survival (HR 3.65) in patients with non-small cell lung cancer.
Why the study?
Does high periostin expression predict decreased cancer-specific survival in patients with non-small cell lung cancer?
Cohort (n=184)
No
Does high periostin expression predict decreased cancer-specific survival in patients with non-small cell lung cancer?
Hazard Ratio: 3.65 (95% CI 1.04–12.84)
Absolute Event Rate: 77.6% vs 94.4%
p-value: p=0.0439
Intratumoral periostin expression is an independent prognostic factor for decreased cancer-specific survival in non-small cell lung cancer.
Periostin may refine NSCLC prognostication; leaves open its clinical utility pending prospective validation.
Periostin is an extracellular matrix N-glycoprotein that is a major constituent of the desmoplastic stroma around solid tumors. Periostin promotes tumor invasion and metastasis via epithelial-mesenchymal transition. The aims of this study were to evaluate periostin expression immunohistochemically and quantitatively in patients with non-small cell lung cancer (NSCLC) and to assess any associations with clinical features and prognosis. A total of 184 specimens of NSCLC tissue were investigated, including 134 adenocarcinomas, 39 squamous cell carcinomas, and 11 other histologic subtypes. The intra-tumoral periostin expression area in each captured field was calculated using the image processing integration software WinROOF. The mean periostin expression score was classified as high or low by the median value of its expression area. Univariate analysis demonstrated that gender, tumor size, T status, N status, stage, histologic type, smoking habits, percent vital capacity, 1% forced expiratory volume, and pleural invasion were each significantly associated with periostin scores. Multivariate analysis revealed that high periostin expression score was an independent prognostic factor significantly associated with decreased cancer-specific survival (HR, 3.65; 95% CI, 1.04-12.84; P=0.0439). We concluded that intratumoral periostin expression was an independent prognostic factor for NSCLC.
No takes yet. Share an insight, caveat, or question.
Murakami et al. (2017) conducted a cohort in Non-small cell lung cancer (NSCLC) (n=184). High periostin expression vs. Low periostin expression was evaluated on Cancer-specific survival (CSS) (HR 3.65, 95% CI 1.04-12.84, p=0.0439). High intra-tumoral periostin expression was an independent prognostic factor significantly associated with decreased cancer-specific survival (HR 3.65) in patients with non-small cell lung cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: